

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
tk Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitu	ite for form 1449A/B	/PTO		Complete if Known		
				Application Number	10/614,990-Conf. #8196	
INF	ORMATIC	ON DISC	LOSURE	Filing Date	July 9, 2003	
STA	ATEMENT	BY AP	PLICANT	First Named Inventor	Henrik S. Olsen	
				Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	C. J. Nichols	
Sheet	1	of	3	Attorney Docket Number	PF108P2D1	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where ' Relevant Passages or Relevant Figures Appear		
3	BA	US-09/912,292	PUBLISHED	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS:23831 and 23838.		
(ZV)	BB	US-09/912,293	PUBLISHED	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 62913 and 194330.		
8	ВС	US-2002/0137081	09-26-2002	Olga Bandman			
\mathcal{C}_{∞}	BD	US-5,877,290	03-02-1999	Oisen et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120. 'Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature Date Considered 4705



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/614,990-Conf. #8196 INFORMATION DISCLOSURE Filing Date July 9, 2003 STATEMENT BY APPLICANT First Named Inventor Henrik S. Olsen Art Unit 1647 (Use as many sheets as necessary) **Examiner Name** C. J. Nichols 2 Sheet of 3 PF108P2D1 Attorney Docket Number

			FOREI	GN PATENT D	OCUMENTS		
Exami		Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	Т
Initials*		No.1	Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T
<i>⁄</i> ‰		BE	WO-96/13610	05-09-1996	Geron Corp.		〒
1		BF	WO-98/20165	05-14-1998	Whitehead Institute for		
Ш					Biomedical Research		
	l	BG	WO-00/16795	03-30-2000	Snow Brand Milk	Abstract and	T
					Products Co., Ltd.	SEQ ID NOS:3	
	\dashv					and 4.	
1 1	l	вн	WO-00/55174	09-21-2000	Human Genome	Pages 1-612 of	T
		•			Sciences, Inc.	Specification	
1	l					and pages 342-	
	ı					343 and 1244-	l
	- 1					1245 of	
	- [Sequence	
	- {					Listing	
1 }						containing SEQ ID NOS: 486	1
	i					and 1426. ?	
-		BI	WO-01/30969	05-03-2001	Human Genome	and 1420. /	╁
	İ	٠.	110 01100000	00-03-2001	Sciences, Inc.		┼
		BJ	WO-01/32209	05-10-2001	Diadexus, Inc.		!
\vdash		BK	WO-01/40269	06-07-2001	Corixa Corp.		二
		BL	WO-01/57271	08-09-2001	Aeromica, Inc.		
\vdash	\rightarrow	BM	WO-02/04013	01-17-2002	BML, Inc.	Abstract and	╁
}	- 1				J. 1110.	Figures, esp.	
ll		•			1	Figure 1.	
		BN	WO-02/060317	08-08-2002	Corixa Corp.	F	\vdash
IT	T	во	WO-02/074979	09-26-2002	Ortho-Clinical	Complete	Γ
					Diagnostics, Inc.	Specification	
						and Figures and	1
						page 28 of	-
					1	Sequence	
						Listing	
11.					1	containing SEQ	1
₩			WO 00/005005	40.04.555	 	ID NO:36.	Ļ_
<u></u>	\leq	BP	WO-02/085308	10-31-2002	Epigenesis		L
ς λ	=1		<u> </u>	<u> </u>	Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk ("') next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120. "Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.uspto.gog or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document." Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English language Translation is attached."

_



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/614,990-Conf. #8196	
INF	ORMATIC	ON DISC	CLOSURE	Filing Date	July 9, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Henrik S. Olsen	
				Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	C. J. Nichols	
Sheet	3	of	3	Attorney Docket Number	PF108P2D1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
دوي	BQ	WAGNER, et al., "Immunological and biological evidence for a stanniocalcin-like hormone in human kidney," <i>Proc. Natl. Acad. Sci. USA</i> 92:1871-1875 (Mar. 1995).	-
	BR	YAMASHITA et al., "The complete amino acid sequence of chum salmon stanniocalcin, a calcium-regulating hormone in teleosts," <i>Molec. and Cell. Endocrin.</i> 112:159-167 (1995)	
	BS	SUNDELL et al., "Chum salmon (Oncorhynchus keta) stanniocalcin inhibits in vitro intestinal calcium uptake in Atlantic cod (Gadus morhua)," <i>J. Comp. Physiol. B</i> 162:489-495 (1992)	
	ВТ	HULOVA et al., "Assignment of Disulfide Linkages in Chum Salmon Stanniocalcin" Biochem. and Biophys. Res. Comm. 257:295-299 (1999)	
	BU	GenBank Accession No. AF242179, JEFFREY et al., "Homo sapiens stanniocalcin 1 (STC1) gene, exons 1 through 4 and complete cds" (Feb. 21, 2002)	
	BV	GenBank Accession No. AF257506, G.E. DIMATTIA, "Bos taurus stanniocalcin mRNA, complete cds" (May 9, 2000)	
V	BW	GenBank Accession No. AZ754534, BARBER et al., "cq01b02.f1 Pax3 CASTing Library 'cq' Mus musculus genomic clone cq01b02 random, genomic survey sequence" (Mar. 1, 2001)	_
دوي	BX	GenBank Accession No. BH042878, ZHAO et al., "RPCI-24-313A13.TJ RPCI-24 Mus musculus genomic clone RPCI-24-313A13, genomic survey sequence" (Jul. 17, 2001)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/F	ото		Complete if Known			
				Application Number	09/840,989		
11	VEORMATIO	ON DISC	CLOSURE	Filing Date	April 25, 2001		
S	STATEMEN	T BY AP	PLICANT	First Named Inventor	Henrik S. Olsen		
				Art Unit	1647		
	(use as man)	sheets as ned	essary)	Examiner Name	C. Saoud		
Sheet	1	of	2	Attorney Docket Number	PF108P2		

	U.S. PATENT DOCUMENTS							
Examiner Initials*		Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Ŝ	2	Α	5,447,841	09-05-1995	Gray et al.			
	T	В	5,491,224	02-13-1996	Bittner et al.			
		С	5,538,869	07-23-1996	Siciliano et al.			
		D	5,545,524	08-13-1996	Trent et al.			
V		E	5,837,498	11-17-1998	Olsen et al.			
(3)	2	F	5,994,301	11-30-1999	Olsen et al.			

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant			
Initials* No		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	76		
	G	WO 88/03949 (PCT)	06-02-1988	Howard Florey Institute of				
50			ļ	Experimental Physiology and Medicine				
6	Н	WO 95/24411 (PCT)	09-14-1995	Human Genome Sciences,				
لخيرا				Inc.		'		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
650	1	BUTKUS et al. "Purification and cloning of a corpuscles of stannius protein from Anguilla australis", Mol. & Cell. Endocrin. 54:123-133 (1987)				
	J	HADDAD et al. "Immunocytomchemical localization of stanniocalcin cells in the rat kidney" Endocrinol. 137(5): 2113-2117 (1996)				
V	К	LAFEBER et al. "Identification of hypocalcin (teleocalcin) isolated from trout stannius corpuscles", Gen. & Comparative Endocrin. 69:19-30 (1988)				
<i>D</i> D	L	MILLIKEN et al. "Effects of synthetic peptide fragments of teleocalcin (hypocalcin) on calcium uptake in juvenile rainbow trout (Salmo gairdneri)" Gen. & Comparative Endocrin. 77:416-422 (1990)	_			

	·		
Examiner Signature	110	Date Considered	417/05
9			

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control purpose.

Under	he Paperwork Reduction	Act of 1995,	no persons are required to r	espond to a collection of inform	nation unless it contains a valid OMB control number	
Sut	stitute for form 1449A/F	PTO		Complete if Known		
				Application Number	09/840,989	
11	NFORMATIC	ON DIS	SCLOSURE	Filing Date	April 25, 2001	
S	TATEMEN	T BY A	PPLICANT	First Named Inventor	Henrik S. Olsen	
				Art Unit	1647	
	(use as many	sheets as i	necessary)	Examiner Name	C. Saoud	
Sheet	2	of	2	Attorney Docket Number	PF108P2	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
(C)	M	OLSEN et al. "Human stanniocalcin: a possible hormonal regulator of mineral	
- 80		metabolism" PNAS USA 93:1792-1796 (1996)	
)	Ν	STERN et al. "Salmon stanniocalcin and bovine parathyroid hormone have dissimilar	-
-		actions on mammalian bone", J. Bone & Mineral Res. 6(11):1153-1159 (1991)	
{	О	WAGNER et al. "Human stanniocalcin inhibits renal phosphate excretion in the rat",	
_		J. Bone & Mineral Res. 12(2):165-171 (1997)	
1 1	Р	WAGNER et al. "Molecular cloning and cDNA sequence analysis of coho salmon	
		stanniocalcin", Mol. & Cell. Endocrin. 90(1):7-15 (1992/1993)	
- 1	Q	WAGNER et al. "Studies on the regulation and characterization of plasma	
		stanniocalcin in rainbow trout", Mol. & Cell. Endocrin. 79:129-138 (1991)	
	R	CHANG et al. "A novel human cDNA highly homologous to the fish hormone	
		stanniocalcin", Mol Cell Endocrinol. 112(2):241-7 (1995)	
	S	MADSEN et al. "Stanniocalcin: a novel protein regulating calcium and phosphate	
\rightarrow		transport across mammalian intestine", Am J Physiol. 274(1 Pt 1):G96-102 (1998)	
-	T	ZHANG et al. "Stanniocalcin: a molecular guard of neurons during cerebral	
		ischemia", Proc Natl Acad Sci U S A. 97(7):3637-42 (2000)	_
1 1	U	ZHANG et al. "High expression of stanniocalcin indifferentiated brain neurons", Am J	
		Pathol. 153(2):439-45 (1998)	
1 1	٧	ZHANG et al. "Expression, purification, and bioassay of human stanniocalcin from	
1 1		baculovirus-infected insect cells and recombinant CHO cells", Protein Expr Purif.	l
		12(3):390-8 (1998)	
	W	BIKFALVI et al. "Biological Roles of Fibroblast Growth Factor-2", Endocrine Reviews	
		18(1):26-45 (1997)	
1 1	X	APFEL "Neurotophic Factor Therapy-Prospects and Problems", Clin. Chem. Lab.	
		Med. 39(4):351-355 (2001)	
	Υ	GOLDSBY et al. "Kuby: Immunology", Cytokines 12:303-327 (2002)	_
\bot	Z	KANDEL et al. "Principles of Neural Science", Neurotransmitters 15:280-297 (2002)	
	AA	BORK et al. Trends in Genetics 12:425-427 (1996)	
	AB	BRENNER Trends in Genetics 15:132-133 (1999)	
	AC	SMITH et al. Nature Biotechnology 15:1222-1223 (November 1997)	
	AD	DOERKS et al. Trends in Genetics 14:248-250 (1998)	
	AE	SKOLNICK et al. Trends in Biotech. 18(1):34-39 (2000)	
	AF	BORK Genome Res. 10:398-400 (2000)	_
	AG	NGO et al. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-	
<u></u>		495 (1992)	
22	AH	WELLS Biochem. 29:8509-8517 (1990)	
			-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature / / / / / / / / / / / / / / / / / / /	Date Considered 4/7/05

^{&#}x27;Applicant's unique citation designation number (optional), 'Applicant is to place a check mark here if English language Translation is attached.